세계의 파브라자임(Fabrazyme) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Fabrazyme Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,290,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,091,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,893,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

파브라자임 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간 동안의 성장은 파브리 병에 대한 인식 향상, 유전자 검사 기술의 발전, 환자 수 증가, 규제 지원 및 보험 적용 정책, 희귀 질환에 대한 집중 등이 주요 요인으로 작용할 것입니다. 예측 기간의 주요 동향으로는 진단율 증가, 기술 발전, 신흥 시장 확대, 지속 가능성 이니셔티브 및 디지털 전환이 있습니다.

유전 질환의 유병률이 증가함에 따라 파브라자임 시장의 성장이 촉진될 것으로 예상됩니다. 유전 질환은 개인의 유전 물질의 이상으로 인해 발생하는 건강 상태입니다. 유전 질환의 증가는 주로 더 많은 사례를 발견하는 첨단 진단 기술과 함께, 부모의 출산 연령 지연, 환경적 영향, 유전적 변이에 기여하는 생활 방식의 변화와 같은 요인에 기인합니다. 파브라자임은 알파-갈락토시다제 A 효소 결핍으로 인한 유전성 질환인 파브리 병을 치료하기 위한 효소 대체 요법입니다. 이 약물은 체내에 축적되는 특정 지질을 분해하여 장기 손상 위험을 줄이고 증상을 완화하며 전반적인 삶의 질을 개선합니다. 예를 들어, 2024년 3월 영국 기반 자선 단체 Gene People은 영국에서 6,000개 이상의 유전적 질환이 진단되었으며, 이는 약 25명 중 1명의 어린이에게 영향을 미친다고 보고했습니다. 이는 연간 약 30,000건의 신규 진단 사례를 발생시키며, 현재 약 240만 명이 유전적 질환을 앓고 있습니다. 따라서 유전적 질환의 증가가 파브라자임 시장 성장을 촉진하고 있습니다.

의료비 지출의 증가는 파브라자임 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 의료비 지출은 의료 서비스 및 관련 활동에 지출된 총 금액을 의미하며, 일반적으로 매년 측정됩니다. 의료비 지출의 증가는 인구 고령화, 만성 질환, 서비스 가격 상승, 수요 증가, 기술 발전, 의약품 비용 상승 등의 요인에 기인합니다. 파브라자임은 효소 대체 요법을 통해 파브리 병의 근본 원인을 치료하며, 이는 의료비 지출 증가로부터 혜택을 받습니다. 이는 질병 관리 개선, 고비용 응급 치료 필요성 감소, 환자 예후 개선을 가능하게 하기 때문입니다. 예를 들어, 국립 의료 도서관 보고서에 따르면, 의료비 지출은 2022년 4.1% 증가했으며, 2021년 3.2% 증가한 4조 5,000억 달러에 이르렀습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 파브라자임 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 파브라자임 시장 : 성장률 분석
• 세계의 파브라자임 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 파브라자임 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 파브라자임 : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 파브라자임 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 5mg/바이알
• 35mg/바이알
• 세계의 파브라자임 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 파브리 병
• 신장 기능 장애
• 심장 병변
• 신경장애성 통증
• 뇌졸중 예방
• 세계의 파브라자임 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 약국
• 세계의 파브라자임 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아
• 성인

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 파브라자임 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 파브라자임 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 파브라자임 시장 : 경쟁 구도
• 파브라자임 시장 : 기업 프로파일
  • Sanofi SA
  • JCR Pharmaceuticals
  • mAbxience

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 파브라자임 시장(2029년) : 새로운 기회를 제공하는 국가
• 파브라자임 시장(2029년) : 새로운 기회를 제공하는 부문
• 파브라자임 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Fabrazyme is a prescription medication primarily used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency results in the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues, leading to serious health complications such as kidney damage, heart issues, and neurological problems.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of fabrazyme include the 5 mg/vial and 35 mg/vial formulations. The 5 mg/vial refers to Fabrazyme supplied in single-dose vials containing 5 milligrams of the active ingredient, agalsidase beta. These formulations are used in hospitals and drug stores, with end users including both pediatric and adult patients.

The fabrazyme market research report is one of a series of new reports from The Business Research Company that provides fabrazyme market statistics, including fabrazyme industry global market size, regional shares, competitors with a fabrazyme market share, detailed fabrazyme market segments, market trends and opportunities, and any further data you may need to thrive in the fabrazyme industry. This fabrazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fabrazyme market size is expected to see rapid growth in the next few years. It will grow to $2,079.6 million in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing recognition of Fabry disease, advancements in genetic testing, rising patient population, regulatory Support and reimbursement policies, and focus on rare diseases. Major trends in the forecast period include increasing diagnosis rates, technological advancements, emerging market expansion, sustainability initiatives, and digital transformation.

The increasing prevalence of genetic disorders is expected to drive the growth of the fabrazyme market. Genetic disorders are health conditions caused by abnormalities in an individual's genetic material. The rise in genetic disorders is largely due to advanced diagnostic technologies detecting more cases, along with factors like delayed parenthood, environmental influences, and lifestyle changes contributing to genetic mutations. Fabrazyme, an enzyme replacement therapy, is used to treat Fabry disease, a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. It helps break down certain lipids that accumulate in the body, reducing organ damage risk, alleviating symptoms, and improving overall quality of life. For instance, in March 2024, Gene People, a UK-based charity, reported that over 6,000 genetic conditions are diagnosed in the UK, affecting approximately 1 in 25 children. This results in about 30,000 new diagnoses annually, with more than 2.4 million people currently living with a genetic condition. Therefore, the rising number of genetic disorders is propelling the fabrazyme market.

Increasing healthcare expenditure is expected to further drive the growth of the fabrazyme market. Healthcare expenditure refers to the total amount spent on health services and related activities, typically measured annually. The rise in healthcare expenditure is attributed to factors such as an aging population, chronic diseases, higher service prices, increased demand, technological advancements, and rising drug costs. Fabrazyme addresses the underlying causes of Fabry disease through enzyme replacement therapy, which benefits from increased healthcare spending as it allows for better disease management, reduces the need for costly emergency interventions, and ultimately improves patient outcomes. For example, the National Library of Medicine reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, faster than the 3.2% growth seen in 2021. Therefore, rising healthcare expenditure is fueling the growth of the fabrazyme market.

The rise of personalized medicine is expected to contribute to the growth of the fabrazyme market. Personalized medicine is a treatment approach that tailors healthcare strategies to an individual's genetic makeup, environment, and lifestyle, aiming for more effective and precise outcomes. The rise in personalized medicine is driven by advancements in genomic technologies, a greater understanding of molecular biology, increased availability of precision diagnostic tools, and a demand for targeted therapies that enhance patient outcomes while minimizing side effects. Fabrazyme supports personalized medicine by providing enzyme replacement therapy tailored to the specific genetic and metabolic needs of patients with Fabry disease, improving therapeutic efficacy and clinical outcomes. For example, in 2022, the FDA approved personalized medicines for 34% of new drugs, according to the Personalized Medicine Coalition. This demonstrates the growing trend in personalized medicine, which is driving the fabrazyme market forward.

Major players operating in the fabrazyme market are Sanofi S.A., JCR Pharmaceuticals, mAbxience

North America was the largest region in the Fabrazyme market in 2024. The regions covered in fabrazyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabrazyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabrazyme market consists of sales of the enzyme replacement therapy (ERT) known as Fabrazyme (agalsidase beta), Replagal (agalsidase alpha), Oral Chaperone Therapies, Substrate Reduction Therapies (SRT). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabrazyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabrazyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabrazyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabrazyme market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 5mg/vial; 35mg/vial
• 2) By Indication: Fabry Disease; Renal Impairment; Cardiac Involvement; Neuropathic Pain; Stroke Prevention
• 2) By Application: Hospital; Drug store
• 3) By End-User: Pediatric; Adult
• Companies Mentioned: Sanofi S.A.; JCR Pharmaceuticals; mAbxience
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fabrazyme Market Characteristics

3. Fabrazyme Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Fabrazyme Market Trends And Strategies

5. Fabrazyme Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Fabrazyme Growth Analysis And Strategic Analysis Framework

• 6.1. Global Fabrazyme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Fabrazyme Market Growth Rate Analysis
• 6.4. Global Fabrazyme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Fabrazyme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Fabrazyme Total Addressable Market (TAM)

7. Global Fabrazyme Market Pricing Analysis & Forecasts

8. Fabrazyme Market Segmentation

• 8.1. Global Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5mg/vial
• 35mg/vial
• 8.2. Global Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fabry Disease
• Renal Impairment
• Cardiac Involvement
• Neuropathic Pain
• Stroke Prevention
• 8.3. Global Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Drug store
• 8.4. Global Fabrazyme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult

9. Global Fabrazyme Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Fabrazyme Market Regional And Country Analysis

• 10.1. Global Fabrazyme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Fabrazyme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Fabrazyme Market

• 11.1. Asia-Pacific Fabrazyme Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Fabrazyme Market

• 12.1. China Fabrazyme Market Overview
• 12.2. China Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Fabrazyme Market

• 13.1. India Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Fabrazyme Market

• 14.1. Japan Fabrazyme Market Overview
• 14.2. Japan Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Fabrazyme Market

• 15.1. Australia Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Fabrazyme Market

• 16.1. South Korea Fabrazyme Market Overview
• 16.2. South Korea Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Fabrazyme Market

• 17.1. Western Europe Fabrazyme Market Overview
• 17.2. Western Europe Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Fabrazyme Market

• 18.1. UK Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Fabrazyme Market

• 19.1. Germany Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Fabrazyme Market

• 20.1. France Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fabrazyme Market

• 21.1. Eastern Europe Fabrazyme Market Overview
• 21.2. Eastern Europe Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Fabrazyme Market

• 22.1. North America Fabrazyme Market Overview
• 22.2. North America Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Fabrazyme Market

• 23.1. USA Fabrazyme Market Overview
• 23.2. USA Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Fabrazyme Market

• 24.1. Canada Fabrazyme Market Overview
• 24.2. Canada Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Fabrazyme Market

• 25.1. South America Fabrazyme Market Overview
• 25.2. South America Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Fabrazyme Market

• 26.1. Middle East Fabrazyme Market Overview
• 26.2. Middle East Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Fabrazyme Market

• 27.1. Africa Fabrazyme Market Overview
• 27.2. Africa Fabrazyme Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Fabrazyme Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Fabrazyme Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Fabrazyme Market Competitive Landscape And Company Profiles

• 28.1. Fabrazyme Market Competitive Landscape
• 28.2. Fabrazyme Market Company Profiles
  • 28.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. JCR Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. mAbxience Overview, Products and Services, Strategy and Financial Analysis

29. Global Fabrazyme Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Fabrazyme Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Fabrazyme Market

32. Recent Developments In The Fabrazyme Market

33. Fabrazyme Market High Potential Countries, Segments and Strategies

• 33.1 Fabrazyme Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Fabrazyme Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Fabrazyme Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer